Pharmaceutical Industry
Filter News
Found 36,216 articles
-
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
-
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
12/1/2021
ALK announced that results from the REACT study, a large retrospective real-world study comprising more than 92,000 patients with respiratory allergies, have been published in the research journal, The Lancet Regional Health – Europe 00261-1/fulltext) – a regionally-focused journal from the publisher of the world's leading medical research journal, The Lancet.
-
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
12/1/2021
Sanofi announced it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.
-
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders
12/1/2021
Bionomics Limited, a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration has granted Fast Track designation to the BNC210 development program for the acute treatment of Social Anxiety Disorder and other anxiety-related disorders.
-
Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement
12/1/2021
Notable Labs, Inc., a clinical-stage predictive precision therapeutics company and CicloMed LLC, a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia under the terms of a co-development agreement.
-
Helixmith Announces 50% Enrollment in its Clinical Trial for COVID-19, involving TADIOS
12/1/2021
Helixmith Co., Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects.
-
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
12/1/2021
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the journal Molecular Therapy – Methods and Clinical Development has published the results of a mechanistic study demonstrating the transfer of LUMEVOQ® vector DNA from the injected eyes to the non-injected eyes of non-human primates.
-
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
12/1/2021
Sanofi hosts a hybrid Vaccines Investor Event with key members of the Vaccines leadership team to discuss how the company applies the global Play to Win strategy to pursue growth opportunities and to build an industry-leading vaccines pipeline.
-
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
-
Deciphera Pharmaceuticals announced it is restructuring with the intention of prioritizing clinical development of specific programs and streamlining its commercial operations.
-
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze's products to the greater China market.
-
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
-
One day after falsified information regarding its Phase I/II breast cancer data circulated online, Olema Pharmaceuticals released its topline data for a potential best-in-class complete estrogen receptor antagonist.
-
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
-
Elizabeth Holmes blames the allegations of investor fraud perpetrated by her blood-testing company Theranos at the feet of her former business partner Ramesh “Sunny” Balwani.
-
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
-
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
11/30/2021
Blade Therapeutics, Inc. today announced positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.
-
Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
11/30/2021
Biomica reported today positive results from pre-clinical studies in its IBD program.
-
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
11/30/2021
Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor antagonist and a selective ER degrader in development for the treatment of metastatic breast cancer and other women’s cancers.
-
Pardes Biosciences Appoints New Chief Business and Strategy Officer
11/30/2021
Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, announced that Philippe Tinmouth has been appointed as Chief Business and Strategy Officer.